Related Experiment Video
Updated: Aug 15, 2026
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
Tranexamic acid significantly reduces blood loss associated with coronary revascularization
J A Rousou1, R M Engelman, J E Flack
1Division of Cardiac Surgery, Baystate Medical Center, Springfield, Massachusetts 01107.
Insights
Tranexamic acid (TA) significantly reduced blood loss and the need for blood transfusions in patients undergoing coronary revascularization surgery. While no increased thrombotic complications were clearly demonstrated, they should not be overlooked.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Anesthesiology
Background:
- Coronary revascularization procedures often involve cardiopulmonary bypass, leading to coagulopathy and increased blood loss.
- Blood product transfusions are frequently required to manage bleeding complications, increasing patient risk and healthcare costs.
- Tranexamic acid (TA) is a hemostatic agent that may mitigate bleeding in surgical settings.
Purpose of the Study:
- To evaluate the efficacy of tranexamic acid (TA) in reducing blood loss and transfusion requirements during coronary revascularization.
- To assess the safety of TA by examining the incidence of thrombotic complications.
Main Methods:
- A prospective study involving 415 patients undergoing coronary revascularization over 12 months.
- Patients were divided into two groups: a control group (no TA) and a treatment group (received TA before cardiopulmonary bypass).
- Demographics, surgical techniques, blood loss, and blood product usage were compared between groups.
Main Results:
- The TA group showed significantly reduced postoperative blood loss (803.7 mL vs. 1114.1 mL in controls, p < 0.001).
- TA significantly decreased red blood cell (0.69 vs. 1.7 units/patient, p < 0.001), fresh frozen plasma (0.024 vs. 0.23 units/patient, p < 0.01), and platelet transfusions (0.30 vs. 1.06 units/patient, p < 0.01).
- A higher percentage of patients in the TA group received no blood products (65% vs. 49% in controls, p < 0.01).
- No significant difference in thrombotic complications (myocardial infarction, stroke, embolism, thrombosis) was observed.
Conclusions:
- Tranexamic acid (TA) is highly effective in reducing blood loss and transfusion needs in patients undergoing coronary revascularization with cardiopulmonary bypass.
- The study did not demonstrate a clear increase in thrombotic events with TA, but vigilance is warranted.
- TA profoundly impacts coagulopathy associated with bypass, improving surgical outcomes.
Abstract:
Four hundred fifteen patients undergoing coronary revascularization over a 12-month period were divided into two groups: 209 controls in the first 6 months received no tranexamic acid (TA) before cardiopulmonary bypass and 206 patients in the second 6 months received TA as a hemostatic agent. The demographics and the surgical techniques used were similar in the two groups. With TA there was a significant decrease in blood loss postoperatively, from 1,114.1 mL in the controls to 803.7 mL in those given TA (p < 0.001); in red blood cell use, from 1.7 units/patient in the controls to 0.69 units/patient in those given TA (p < 0.001); in fresh frozen plasma requirements, from 0.23 units/patient in the controls to 0.024 units/patient in those given TA (p < 0.01); and in platelet transfusion, from 1.06 units/patient in the controls to 0.30 units/patients in those given TA (p < 0.01). The percentages of patients not receiving any blood products were 65% in those given TA versus 49% in the controls (p < 0.01). There was no significant difference between the two groups in the incidence of perioperative myocardial infarction, cerebrovascular accidents, pulmonary embolism, or venous thrombosis to clearly suggest hypercoagulability. In this study, TA profoundly affected the coagulopathy associated with bypass in patients undergoing coronary revascularization. It significantly reduced blood loss and blood product transfusions. Any potential increased thrombotic complications could not be clearly demonstrated in this study, but should not be ignored.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Acute Coronary Syndrome I: Introduction
01:29Venous Thrombosis III: Interprofessional Care